Metabolic and functional heterogeneity in pancreatic β cells

Da Silva Xavier, Gabriela; Rutter, Guy A

DOI:

[10.1016/j.jmb.2019.08.005](https://doi.org/10.1016/j.jmb.2019.08.005)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Da Silva Xavier, G & Rutter, GA 2019, 'Metabolic and functional heterogeneity in pancreatic β cells', *Journal of Molecular Biology*. <https://doi.org/10.1016/j.jmb.2019.08.005>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Da Silva Xavier, G. & Rutter, A. (2019) Metabolic and functional heterogeneity in pancreatic β cells, *Journal of Molecular Biology*, <https://doi.org/10.1016/j.jmb.2019.08.005>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Coordinated network
+ Glucose, GLP-1, etc

Insulin

Impaired connectivity
+ Glucose, GLP-1, etc

Metabolic and functional heterogeneity in pancreatic β cells.

Gabriela Da Silva Xavier¹ and Guy A. Rutter^{2,3}

¹Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Edgbaston, United Kingdom; ²Section of Cell Biology and Functional Genomics, Department of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom and ³Lee Kong Chian School of Medicine, Nan Yang Technological University, Singapore

Gabriela da Silva Xavier (g.dasilvaxavier@bham.ac.uk; +44 (0)1214158705)

Guy A. Rutter (G.Rutter@imperial.ac.uk; +44 (0)20 7594 3340)

Declarations of interest: none

Keywords: Islets of Langerhans; β cells; insulin; metabolism; heterogeneity

Highlights:

- Pancreatic β cells exhibit metabolic heterogeneity
- Metabolic heterogeneity is critical for the regulation of insulin secretion
- Hub β cells coordinate the action of other β cells within the islet
- β cell sub-populations can be characterised by their specific gene expression profiles

Abstract

Metabolic and secretory heterogeneity are fundamental properties of pancreatic islet β cells. Emerging data suggest that stable differences in the transcriptome and proteome of individual cells may create cellular hierarchies which, in turn, establish coordinated functional networks. These networks appear to govern the secretory activity of the whole islet and be affected in some forms of diabetes mellitus. Functional imaging, e.g. of intracellular calcium dynamics, has led to the demonstration of “small worlds” behaviour, and the identification of highly connected “hub” (or “leader”) cells, and of follower populations subservient to them. Subsequent inactivation of members of either population, for example using optogenetic approaches or photoablation, has confirmed the importance of hub cells as possible pacemakers. Hub cells appear to be enriched for the glucose phosphorylating enzyme glucokinase, and for genes encoding other enzymes involved in glucose metabolism, compared to follower cells. Recent findings have shown the relevance of cellular hierarchy in islets from multiple species including human, mouse and fish, and shown that it is preserved *in vivo* in the context of the fully vascularised and innervated islet. Importantly, connectivity is impaired by insults which mimic the diabetic milieu, including high glucose and/or fatty levels, and by the ablation of genes associated with type 2 diabetes risk in genome-wide association studies. We discuss here the evidence for the existence of these networks and their failure in disease settings. We also briefly survey the challenges in understanding their properties.

Introduction:

Loss of functional pancreatic β cell mass underpins the development of both Type 1 and Type 2 diabetes (T2D) [1-4]. Environmental and genetic factors contribute to the loss of functional β cell mass in T2D (reviewed in [5, 6]). The β cell is the only source of circulating insulin and the loss of regulated insulin secretion leads to dysregulated energy homeostasis.

The notion that not all β cells are the same has received much recent interest, yet is far from new. Thus, a number of studies since the 1960s have reported that β cells exhibit, for example, different sensitivities to glucose, and distribution and numbers within any given islet, and that heterogeneity is linked to differences in ability to secrete insulin [7-22]. There are also published data [23-32] to indicate that there is heterogeneity in the distribution of islets themselves between different parts of the pancreas, [33, 34], though recent data question this possibility in healthy human pancreata [35]. It should be emphasized that functional heterogeneity is not unique to β cells. For example, pituitary cells have been shown to exhibit heterogeneous response to hormonal stimulation [36-38]. Importantly, in recent years the repurposing by us and others of technologies developed to map the heterogeneity in the pituitary response for the study of the pancreatic islet has led to breakthroughs in our understanding of β cell heterogeneity within the context of an islet [39, 40]. In this review, we will look at how β cell heterogeneity contributes to islet function and systemic glucose homeostasis, and how the loss of this heterogeneity may lead to disease. We will focus on the heterogeneous metabolic responses exhibited by β cells and discuss how this affects islet function and glucose homeostasis. We also discuss the implications of heterogeneity for the treatment of diabetes, including β cell replacement therapy.

β cell metabolism is central to secretory function

Islets of Langerhans consists of α , β , δ , polypeptide P (PP) and ϵ cells ([41] and references therein). The rodent islet typically consists of a core of β cells with a mantle of the other cell types [42], whilst human islets exhibit more intermingling of the different cell types [43]. β cells are the predominant cell type in mammalian islets of Langerhans typically comprising ~70% of cells in rodent and ~ 50% in human islets [44]. Islets themselves make up about 0.7% of the volume of the pancreas and are the only source of circulating insulin [45]. β cell function - the ability to release insulin in response to changes in the concentration blood glucose or other stimuli such as incretin hormones - is the sum of cell autonomous function for each β cell within the islet in response to external stimuli and the interaction of the cells within the islet [46].

β cells secrete insulin in response to changes in blood glucose concentration (see Fig. 1; reviewed in [47]). Insulin secretion is tightly regulated through the metabolism of glucose in these cells. The “canonical” pathway for glucose-stimulated insulin secretion is summarised in Figure 1 and is as follows. Glucose is transported in to β cells by the low affinity glucose transporter (GLUT2/SLC2A2): glucose concentrations equilibrate across the plasma membrane as the capacity for transport exceeds that for phosphorylation by the low affinity hexokinase, glucokinase [48]. Glucokinase is not inhibited by its own product, exhibits positive cooperativity at 4-10 mM glucose (i.e. within the normal physiological range) and has no/low specificities for other hexoses at physiologically relevant concentrations [49]. Gluconeogenesis is low in β cells due to limited phosphoenolpyruvate carboxykinase and fructose 1,6-bisphosphatase expression (www.biogps.org). Thus, glucose transport [50] and glucose phosphorylation [51] are important control points which contribute to the overall characteristics of insulin release observed *in vivo.*, with glucokinase serving as the key “flux generating” [52-55] step in glycolytic metabolism.

ATP (or, more precisely, ATP/ADP ratio) is a central intracellular regulator of insulin release.

Moreover, mitochondrial metabolism of glycolytically-derived pyruvate and NADH are central to glucose sensing by pancreatic β cells [56-59]. Additionally, pyruvate carboxylase favours flux of pyruvate-derived carbons in to the tricarboxylic cycle, providing “anaplerotic” input to maintain adequate levels of citrate cycle intermediates [60, 61]. Uniquely in β cells, glycolytic flux is closely coupled to oxidative phosphorylation by suppression of lactate dehydrogenase (LDHA) [53, 62, 63] and monocarboxylate transporter (MCT-1/SLC16A1) [64-66] (two amongst a host of β cell “disallowed” genes, so called as they are expressed at high levels in other cell types; [67]; see below) expression, alongside high levels of glycerol phosphate dehydrogenase expression [53, 68-70].

Stimulation of intramitochondrial dehydrogenases, and increased mitochondrial membrane potential (occurring downstream of increases in cytosolic calcium concentration), enhance oxidative metabolism in response to high glucose [71-73]. Thus, under normal physiological conditions, β cells are poised to favour glycolytic and oxidative metabolism of glucose [70, 74] over alternative pathways [75], resulting in enhanced ATP synthesis. ATP leads to the closure of ATP-sensitive potassium channels [76, 77], leading to membrane depolarisation and the opening of voltage-gated calcium channels [78, 79]. Calcium entry via voltage-gated Ca^{2+} channels then leads to activation of secretory granule-associated small N-ethylmaleimide-sensitive factor receptor proteins [80], granule fusion with the plasma membrane [81], and insulin release. Aside from the above “ K_{ATP} channel dependent” pathway, insulin secretion is amplified by K_{ATP} -channel independent, glucose metabolism-dependent pathways [59, 82]. Of particular recent interest is a pathway dependent on efflux of mitochondrial citrate and the generation of NAD(P)H in the cytosol [83]. Several other oxidisable metabolites such as leucine, ketoisocaproate and glutamine are able to stimulate insulin release via the same metabolic ATP-dependent signalling pathways downstream of glucose entry [56, 57, 84] (Fig. 1).

Exposure to hyperglycaemia leads to alteration of the expression of the above and other “disallowed” genes involved in β cell metabolism, contributing to the disruption of β cell function [85]. Thus, islets from rats subjected to 90 % pancreatectomy (resulting in exposure to chronic hyperglycaemia) exhibit increased expression of genes involved in gluconeogenesis (glucose-6-phosphatase, fructose-1,6-bisphosphatase), regulation of pyruvate flux (lactate dehydrogenase, monocarboxylate transporters), and mitochondrial function (uncoupling protein 2), and decreased expression of GLUT2, representing loss of the metabolic programme that is characteristic of β cells (Fig. 1).

In summary, the β cell is an glucose sensor *par excellence* due its ability to enhance ATP production through the metabolism of glucose almost exclusively via glycolysis and oxidative phosphorylation [70, 74, 86, 87]. The ability of the β cell to release insulin in response to glucose is intrinsically linked to the unique metabolism exhibited by this cell type.

β cells display heterogeneous metabolic profiles

Individual β cells have different sensitivities to glucose.

It has been known since the 1980s that individual rat islet β cells display different sensitivities to glucose and this had an impact on their ability to synthesise and secrete insulin [7-15]. Rodent β cells increase the synthesis and secretion of insulin in response to glucose by recruiting β cells in a dose-dependent manner [8, 11, 12]. It was found that β cells from dispersed rat islets could be broadly separated in to two groups: high (which secreted insulin avidly) or low (which secreted less insulin) responsive populations [10, 13, 88]. These highly responsive β cells released insulin at lower stimulatory glucose concentrations, and released more insulin in response to glucose in a dose-dependent manner, than the low responsive β cells. High responsive β cells also displayed increased insulin synthesis [7, 10, 13] and preferential release of the newly synthesised insulin [10, 13], but accounted for only a small

proportion of the total β cell population. For example, in rats, only 18% of β cells were highly glucose responsive [7], but this population expands following sustained exposure to high glucose concentrations [88], possibly as an adaptive mechanism. The increased insulin biosynthesis observed in these highly responsive β cells was not associated with altered electrophysiological characteristics of the membrane [14] but was associated with increased glucose-induced metabolism in the highly responsive β cells [7], suggesting that metabolic heterogeneity may account for the functional diversity between the two β cell populations. The above heterogeneity in response to glucose may be beneficial in that it allows fine-tuning of insulin release through the concerted action of β cells with different sensitivities to glucose, and may be a mechanism to avoid hypoglycaemia through excessive insulin release. This phenomenon is also observed in human islets. Antigenically-distinct populations of FACS-purified β cells were shown to have diverse gene expression profiles, and distinct sensitivities to glucose as an insulin secretagogue (as determined by functional assays using pseudo-islet aggregates of purified β cell sub-types) [34]. Some of the differentially expressed genes within these β cell subpopulations in human islets are associated with β cell maturation, glucose metabolism, insulin secretion, and the pathophysiology of type 2 diabetes [34]. These populations of β cells with heterogeneous function are present in normal adult islets and their distribution was found to be altered in type 2 diabetes [34].

The differences in glucose responsiveness are known to be due (at least in part) to differences in the expression of genes encoding for enzymes involved in the regulation of glucose metabolism (discussed in the next section). However, there is evidence that the heterogeneity in metabolic responses may also be due to factors other than the islet cells themselves. For example, two subpopulations of islets which had different abilities to secrete insulin had previously been identified based on the degree of vascularisation occurring in the islets [89]. Thus, islets which were highly vascularised exhibited better β cell function with higher metabolic activity than low-oxygenated islets [89], i.e. metabolic heterogeneity could result

from differential exposure to the cellular environment. It has previously been reported that 20-25 % of the islets in intact rat pancreata were hypoxic; the hypoxic islets had lower metabolic activity and were thought to represent a dormant subpopulation that can be recruited on metabolic demand, which effectively serves as a reserve population that can be activated on demand [90]. Could this population of hypoxic islets be recruited via adaptive alterations in vascularisation induced by changes in the system's metabolic status? This is a question that merits an answer, and can be investigated by using state-of-the-art techniques where islets are grafted in the anterior chamber of the eye, subjected to changes in the milieu, with dynamic imaging of changes in the cells and the surrounding tissue [40, 91-94].

Differences between β cell can be ascribed to altered gene expression.

In the last decade, there has been a renewed interest in β cell heterogeneity, an interest reignited due to the possibility to study this phenomenon using single cell transcriptomics, and other omics, alongside functional analysis of single β cells within the islet. The concept that β cells have a specific gene expression signature is not new, and indeed we have known for over two decades that the expression of certain metabolic and other housekeeping genes are selectively “disallowed” in the β cell (reviewed in [47]). The advent of techniques (e.g. massive parallel sequencing; RNASeq) which allow gene expression screening, in combination with methods for cell type enrichment, gave us a picture of the gene expression profile one could expect from a *single* islet cell. Thus, single cell RNASeq has revealed heterogeneous gene expression between the same type of islet cells (reviewed in [95]), and indicated that our definitions of cell identity may be inadequate. Although limited to the expression of the most abundant transcripts (typically ~ 5,000 transcripts at optimal read depth; this limitation has significant implications for the ability to determine if heterogeneous detection is the same as heterogeneous expression [96]), it has been reported that heterogeneity in the expression of genes is apparent in single β cells and includes genes involved in endoplasmic reticulum stress, β cell maturation and β cell function [97-100]. This approach has led to the identification

of five potentially novel sub-types of β cells [99]. These findings are reminiscent of the four subtypes of human β cells identified based on differences in the abundance of candidate proteins determined using mass cytometry in single human islet cells [101]. Whether increases in heterogeneity can occur as part of the loss of insulin secretory function in disease states including T2D has also been considered [99, 102]. Disruption of expression of some of the genes that have been implicated with increased risk of type 2 diabetes, as identified by genome wide association studies, have also been shown to lead to loss of β cell connectivity [103, 104], further implicating loss of coordinated β cell action as part of the disease mechanism.

Immature β cells display elevated expression of genes that are normally expressed during β cell development, have low insulin content and poor insulin secretion, and gene markers which indicate the potential for proliferation [102, 105, 106], reinforcing the idea that the gene expression programme for proliferation and differentiation are incompatible phenomena [107]. Likewise, β cells that have been exposed to hyperglycaemia dedifferentiate (at least partially) and also display gene expression profiles that are akin to that seen in cells undergoing the β cell developmental programme [85, 102]. Single cell RNASeq of human islets revealed that β cells from type 2 diabetic donors reacquire the gene expression profiles described for developing endocrine cells, suggesting dedifferentiation [100]. A recent study using single cell RNASeq on human islets demonstrated that human islet cells can dedifferentiate and transdifferentiate *ex vivo*, and that gradual cell fate transitions may occur [108] (Fig.2). Thus, Teo and colleagues detected the presence of polyhormonal cells, confirming data from a previous study from the Kaestner group [100]. Another study found overlap in gene expression signatures between major and minor islet cell types [109]. A sub-population of functionally immature β cells that exist at the islet periphery, so called “virgin” (urocortin-3-negative) β cells that represent an intermediate stage in the transdifferentiation of α cells into mature β cells, thought to represent a neogenic niche that serves as a source for β cell

replenishment, were recently identified in mice [110]. Thus, the different subgroups of β cells may represent β cells undergoing gradual cell fate transitions *in vivo* (Fig. 2), with adaptation of the metabolic gene expression profile to allow function given a particular metabolic status. Furthermore, a recent elegant study using isotope microscopy using mouse tissues revealed that pancreatic endocrine cells, including β cells, can have widely varying ages i.e. some β cells replicate whilst others do not [111]; this observation was also made in zebrafish, where functional heterogeneity arose due to the presence of older and younger β cells that display different glucose responsiveness [112]. Could some of the older β cells have had a “previous life” as another cell type?

Alteration of β cell identity may not only pertain to the pathophysiology of type 2 diabetes: Non obese diabetic (NOD) mice were found to harbour a subset of β cells which acquire a senescence-associated secretory phenotype (SASP) which is underpinned by alterations in gene expression [113]. One of the challenges now is to try to amalgamate the information that has been gained through the identification of these various sub-groups to form a coherent road map of β cell function within the environment of an islet. To start with, is there any overlap between the subgroups identified using different markers? Were the different subgroups of β cells generated along defined developmental programmes, or on ones which deviate from the developmental programme that we have currently defined for archetypal β cells? These questions merit answers and painstaking efforts at single cell transcriptomics may yield these answers. However, these studies reveal that our current definition of what constitutes a β cell is probably inadequate and we likely need a better definition to take the field forward. Of note, lineage tracing approaches (e.g. as used in mouse models [114, 115]) are likely to be required to demonstrate cell fate transitions, as recently demonstrated in human islets [116].

β cells within an islet operate as an interconnected, but hierarchical, syncytium: the hub cell hypothesis

One of the possibilities that emerges from the demonstration of β cell heterogeneity is that different subpopulations may adopt discrete roles within a functioning islet syncytium, with individual cells or subgroups performing a controlling or pace-making role through intercellular interactions. We know, for example, that dispersed individual β cells secrete insulin less well than clusters of cells, a gain of function likely due to cell-cell coupling [117] via the presence of cell-to-cell adhesion and/or junctional communication between cells [11, 118-120]. Loss of junctional communication has been shown to lead to altered stimulation threshold and kinetics of insulin release in rodent islets, leading to less efficient insulin secretion in response to nutrient load [118, 119], i.e. the cells in the islets of Langerhans exhibit cooperativity. Moreover, there is heterogeneity in the expression patterns for genes encoding for gap junction proteins in β cells, indicating differences in the connected nature between individual β cells [121]. This phenomenon is found in both rodent and human islets [39, 121, 122], (reviewed in [123]). However, the degree of cooperativity between β cells in human islets was enhanced only in the presence of glucagon-like peptide 1, and was inhibited in the presence of free fatty acids [124]. Human β cells also exhibit heterogeneity, and cooperativity between β cells is a function of this heterogeneity [39].

Importantly, a sub-population of β cells within the islet, which exhibit a less mature phenotype (albeit with some critical exceptions; see below), and have higher mitochondrial membrane potential, appear to be the regulators or “hub” cells which make connections with, and control the activities of, other “follower” β cells [39]. Recently, we have shown that this same hierarchy is apparent in islets engrafted in the anterior chamber of the eye [40], where the islets become revascularised and innervated, as well as in the living fish embryo [40]. In the latter species, photo-ablation of “hub”, but not “follower” cells, led to a loss of islet-wide Ca^{2+} dynamics, confirming a role for these cells in islet pace-making in the living animal. Of note, however, it was recently suggested that cell-cell connectivity and synchronicity was not evident in adult zebrafish islets, which do not express a homologue of mammalian connexin 36 (important for

β cell connectivity in mammalian islets), although the lack of tight cell-cell coupling of intracellular calcium responses did not impair β cell glucose responsiveness [125]. In contrast, our own findings [126] have demonstrated excellent cell-cell coupling and synchronisation in adult fish islets. The reasons for these differing findings are not clear: differences in islet isolation procedure or culture conditions may be involved. Zebrafish have four Cx36-like proteins which display more than 85% homology to mammalian Cx36 [127]. Thus, whilst zebrafish β cells may not express Cx35b [125], it seems quite likely that other Cx36 homologues are expressed and able to form functional gap junctions between zebrafish β cells.

Whilst hub/follower cell ablation experiments have not, as yet, been performed on islets transplanted into the mouse eye, Granger causality analysis – an approach used in finance to identify institutions whose performance predicts that of others across a sector, e.g. banking [128] – showed the existence of “Granger leaders” i.e. likely hub cells, in islets that have been transplanted at this site [40].

Examined *ex vivo*, hub cells displayed increased expression of glucokinase relative to followers, indicating that these cells are sensitised to glucose and have a high metabolic rate [39]. Correspondingly, analysis of published RNASeq data allowed imputation, based on the expression of high levels of *GK* and lower levels of *Pdx1* and *Ins1* in the hub versus the follower population, of elevated levels of other genes involved in glucose oxidation, and defined a tentative transcriptome of these cells [40]. Future studies in which each population is identified and then labelled (e.g. with the use of photo-convertible fluorescent proteins), and subjected to RNASeq, will be required to confirm or refute these findings. Of particular interest will be to establish the stability of each population. Do hubs display a particular localisation e.g. proximity to capillaries or other islet cell types? Of note, our recent findings [40] assessing this behaviour *in vivo* in the anterior eye chamber or living fish embryo indicate that hub/leader

cells tend to be more towards the periphery of the islet than was apparent in isolated islets [39], emphasizing the importance of studying the islet in its native context.

Interestingly, enhanced sensitivity to glucose may also be the reason why these cells are more susceptible to diabetic insults [39] and their loss or dysfunction may thus be critical to islet dysfunction in type 2 and, conceivably, type 1 diabetes.

Is the “less mature” phenotype a consequence of this increased sensitivity to diabetic insults, i.e. dedifferentiation in the face of metabolic stress, or is it a characteristic of this sub-type of β cells? To answer this question, techniques that allow us to trace cell fate over time will be required. This is not a trivial task as the “identity” of the sub-types of cells is defined by the cell’s gene expression programme and there are few methods which allow us to track changes in a substantial number of gene targets in living cells by lineage tracing (see above). Alternatively, we could consolidate the data that is already available to describe different sub-types of β cells, as identified by different cellular/functional markers, and use this reconciled information to guide how we track the cells over time, in a refinement of the approach we have adopted recently [40].

We note that the influence of overall islet function of any one β cell will be determined by signalling events within the cell itself, and by signalling events of neighbouring cells within a syncytium, with a subset of β cells able to influence the actions of a group of others, thereby allowing coordinated islet activity [118], i.e. the islet is in effect a syncytium of mosaic cells. This raises the intriguing possibility that the ability to identify and modulate the activity of these cells, and/or create and replace such cells, may have therapeutic potential.

It is important to note that the hub cell hypothesis has been challenged by data indicating that the manifestation of cellular heterogeneity, as defined by synchronicity of alterations in

intracellular calcium and NAD(P)H responses, are not apparent in earlier studies in the intact islet [119, 120, 129], where the gradient established by glucose entry was found to be more important in determining the strength of response of individual cells within the islet. Echoing these earlier findings, the calcium signal in β cells within an islet where hub cells have been silenced, is diminished in amplitude [39], but temporal synchronisation was still apparent [39], possibly indicating the existence of other pathways for synchronisation. Additionally, where NAD(P)H autofluorescence was measured as an output to assess metabolic heterogeneity, whilst a large proportion of beta cells did not display heterogeneous responses to glucose (leading to the conclusion that metabolic heterogeneity was not important, and supporting the importance of a glucose gradient), a small proportion of the β cells were different in the pattern of their responses, and these regions of differences can be seen in the periphery (where the calcium signal was initiated in response to glucose) and the core (where the calcium signal spread) of the islet [129]. This is not divergent from the hub cell hypothesis, in as much as only a few hub cells display a different metabolic profile [39, 40]. It must be emphasized that imaging experiments providing data both for and against the existence of hub cells have largely been performed using islet cultures in suspension. It is unclear whether the cellular dynamics, potentially induced by diffusion effects affecting glucose concentrations in the islet in such experimental systems [119], exist *in vivo* where glucose is delivered by the capillary network. Our recent careful assessment of the changes in calcium responses in individual β cells within islets *in vivo* in the living zebrafish before and after ablation of the hub cells, and in engrafted mouse islets in the eye chamber subjected to causality analysis (see above) offer further support for the existence of hub cells [39]. Hub deletion assays in the intact perfused pancreas will provide the acid test for the existence of hub cells *in vivo* but represent a considerable challenge.

Translational perspectives

There has been much interest in the ability to preserve, conserve, and/or enhance β cell function, and in β cell replacement either from regeneration or from a heterologous source, as a treatment for diabetes. β cell heterogeneity is an important consideration for all therapeutic strategies since heterogeneity appears to be a component of normal islet function. For example, studies by Meda and colleagues [15] showed that high and low responsive β cells, which together accounted for 75% of the β cell population, retain their enhanced or diminished ability to secrete insulin after multiple stimulations. However, ca 25 % of β cells were able to shift between the two states, i.e. there is a subpopulation of low responsive β cells which are able to shift to a high responsive state. These low responsive cells may indeed be the immature or dedifferentiated β cells that we discussed in an earlier section of this article, which exhibit flexibility in cell identity. Are these cells related to the hub cells that we described in the previous section? Are they the same cells? What about the “sleeping β cells” which have apparently escaped immune destruction that are found in type 1 diabetes (reviewed in [130])? What are the hallmarks of these β cells and could they share the same immature phenotype, to allow them to escape death? Careful cross reference of single cell transcriptomic data obtained from these “different” sub-populations- identified using different cell markers- followed by “wet” tests (e.g. optogenetics, real-time imaging of cells in a more natural environment, etc) may shed light on these questions.

It may be possible to harness the apparent flexibility in cell identity of regenerative subpopulations of β cells for replacement therapy. It is currently unclear whether these flexible cells are from the same cell population that has been previously identified as bihormonal or polyhormonal [100, 102, 108, 131-137], as observed in the foetal pancreas [138, 139], and are more dedifferentiated. The frequency of bihormonal cells are reported to increase in type 2 diabetes [132], but there is currently no information as to how these cells came about and no functional data from such cells, so it is difficult to ascertain what role they may or may not play in metabolic control. To elucidate this we may need methods to allow us to trace cell fate

over time- do these cells “mature” and become functional β cells or do they serve another function? It may be possible to harness the β cell’s ability to shift to a high responsive state (i.e. mature) to enhance functional β cell mass in the diabetic state, an adaptive response which may already exist *in vivo* [88]. It is clear that our current definition of what constitutes a functional β cell is deficient as it is based on the presence of cell maturity markers, the ability to respond to glucose, and the ability to secrete insulin. There are clearly β cells that do not have (all) these properties but do exert important roles in regulating the overall function of the islet [140] and, therefore, glucose homeostasis. In fact, β cells seem to exist on an identity spectrum. Thus, we need to evaluate the bigger picture when we come to assess endocrine pancreas health and function, rather than just focus on the classical parameters we have been using to define cell identity. The fact that not all β cells are the same may also impact on how we interpret functional data that we obtain from our current *in vitro* and *in vivo* genetic manipulation models. Most of these involve a binary on-off switch for the expression of specific genes but in reality the regulation of gene expression in the same cell type within the islet is more nuanced, which asks questions as to how accurately we are replicating the “normal” system outside of the single manipulation that we wanted to effect.

Concluding remarks and future perspectives

Where do the different populations of β cells come from, i.e. can we identify precursor populations for each? If so, do the different sub-populations of β cells follow different developmental programmes? Or could these cells have originated from progenitor cells from different parts of the developing pancreas? Are hub cells permanently tasked to this role, or is there a “duty roster” whereby individual cells are promoted to and then demit from this role? How are signals transmitted from hubs to followers? Our current working model is that most human β cells originate from progenitor cells that follow a particular developmental programme, with β cells dedifferentiating and losing function in the “diseased” state, or

transdifferentiating from other cell types as an adaptive response. Our new insights in to β cell heterogeneity demonstrate that there are certainly still many questions to answer possibly with the advent of new technologies (reviewed in [141]). It is clear that it is insufficient to just have β cells to replicate the precise homeostatic function exerted by the islet *in vivo*. Since the islet operates as an intricate controlled functional unit, in the context of stem cell therapy, is it necessary to recapitulate the whole complement of high and low responsive β cells (and other islet cell types with their heterogeneous counterparts [142]) with correct architecture to recreate an islet that behaves as nature intended? There is still much work to be done.

Acknowledgements

GdSX is supported by an European Foundation for the Study of Diabetes grant and a starter grant from the University of Birmingham. G.A.R. is supported by a Wellcome Trust Investigator (212625/Z/18/Z) Award, MRC Programme grants (MR/R022259/1, MR/J0003042/1, MR/L020149/1) and Experimental Challenge Grant (DIVA, MR/L02036X/1), MRC (MR/N00275X/1), and Diabetes UK (BDA/11/0004210, BDA/15/0005275, BDA 16/0005485) grants. This project has received funding from the European Union's Horizon 2020 research and innovation programme via the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY) to G.A.R.

We thank David Hodson (University of Birmingham, U.K.), Nikolay Ninov (Technical University of Dresden, Germany) and Victoria Salem (Imperial College London, U.K.) for useful discussion.

Figure legends

Figure 1. Canonical pathway for glucose-stimulated insulin secretion. Pathways normally active in the β cell are in black; “disallowed” pathways are in grey.

Figure 2. Fate transitions *in vivo*? There is evidence in the literature that suggests that cells can change identities, possibly adopting intermediate states in between. Mature β cells have been postulated to arise from immature β cells, which may or may not be the same immature cells that constitute hub cells, which in turn can be derived from other islet cell types, pancreatic ductal cells, islet progenitor cells, etc.

References:

- [1] Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes*. 2003;52:102-10.
- [2] Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. *Diabetes Obesity & Metabolism*. 2008;10:32-42.
- [3] Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. *Diabetes*. 2005;54:727-35.
- [4] Marselli L, Suleiman M, Masini M, Bugliani M, Olimpico F, Syed F, et al. Are we overestimating the loss of beta cells in type 2 diabetes? *Diabetologia*. 2013;56:S212-S3.
- [5] Kahn SE, Zraika S, Utzschneider KM, Hull RL. The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. *Diabetologia*. 2009;52:1003-12.
- [6] Rutter GA, Parton LE. The beta-cell in type 2 diabetes and in obesity. *Obesity and Metabolism*. 2008;36:118-34.
- [7] Kiekens R, Tveld PI, Mahler T, Schuit F, Vandewinkel M, Pipeleers D. Differences in Glucose Recognition by Individual Rat Pancreatic B-Cells Are Associated with Intercellular Differences in Glucose-Induced Biosynthetic Activity. *Journal of Clinical Investigation*. 1992;89:117-25.
- [8] Schuit FC, Tveld PAI, Pipeleers DG. Glucose Stimulates Proinsulin Biosynthesis by a Dose-Dependent Recruitment of Pancreatic Beta-Cells. *P Natl Acad Sci USA*. 1988;85:3865-9.
- [9] Vandewinkel M, Pipeleers D. Autofluorescence-Activated Cell Sorting of Pancreatic-Islet Cells - Purification of Insulin-Containing B-Cells According to Glucose-Induced Changes in Cellular Redox State. *Biochem Bioph Res Co*. 1983;114:835-42.
- [10] Vanschravendijk CFH, Kiekens R, Pipeleers DG. Pancreatic Beta-Cell Heterogeneity in Glucose-Induced Insulin-Secretion. *Journal of Biological Chemistry*. 1992;267:21344-8.
- [11] Salomon D, Meda P. Heterogeneity and Contact-Dependent Regulation of Hormone-Secretion by Individual B-Cells. *Exp Cell Res*. 1986;162:507-20.

- 495 [12] Hiriart M, Ramirezmedeles MC. Functional Subpopulations of Individual Pancreatic B-
496 Cells in Culture. *Endocrinology*. 1991;128:3193-8.
- 497 [13] Bosco D, Meda P. Actively Synthesizing Beta-Cells Secrete Preferentially after Glucose
498 Stimulation. *Endocrinology*. 1991;129:3157-66.
- 499 [14] Soria B, Chanson M, Giordano E, Bosco D, Meda P. Ion Channels of Glucose-
500 Responsive and Glucose-Unresponsive Beta-Cells. *Diabetes*. 1991;40:1069-78.
- 501 [15] Giordano E, Bosco D, Cirulli V, Meda P. Repeated Glucose Stimulation Reveals Distinct
502 and Lasting Secretion Patterns of Individual Rat Pancreatic B-Cells. *Journal of Clinical*
503 *Investigation*. 1991;87:2178-85.
- 504 [16] Hellerstrom C, Petersson B, Hellman B. Some properties of the B cells in the islet of
505 Langerhans studied with regard to the position of the cells. *Acta Endocrinol (Copenh)*.
506 1960;34:449-56.
- 507 [17] Dean PM, Matthews EK. Electrical activity in pancreatic islet cells. *Nature*.
508 1968;219:389-90.
- 509 [18] Pipeleers D. The biosociology of pancreatic B cells. *Diabetologia*. 1987;30:277-91.
- 510 [19] Jorns A, Tiedge M, Lenzen S. Nutrient-dependent distribution of insulin and glucokinase
511 immunoreactivities in rat pancreatic beta cells. *Virchows Arch*. 1999;434:75-82.
- 512 [20] Meda P, Halban P, Perrelet A, Renold AE, Orci L. Gap junction development is
513 correlated with insulin content in the pancreatic B cell. *Science*. 1980;209:1026-8.
- 514 [21] Meda P, Amherdt M, Perrelet A, Orci L. Metabolic coupling between cultured pancreatic
515 b-cells. *Exp Cell Res*. 1981;133:421-30.
- 516 [22] Stefan Y, Meda P, Neufeld M, Orci L. Stimulation of insulin secretion reveals
517 heterogeneity of pancreatic B cells in vivo. *J Clin Invest*. 1987;80:175-83.
- 518 [23] Wang X, Misawa R, Zielinski MC, Cowen P, Jo J, Periwai V, et al. Regional differences
519 in islet distribution in the human pancreas--preferential beta-cell loss in the head region in
520 patients with type 2 diabetes. *PLoS One*. 2013;8:e67454.
- 521 [24] Elayat AA, el-Nagggar MM, Tahir M. An immunocytochemical and morphometric study of
522 the rat pancreatic islets. *J Anat*. 1995;186 (Pt 3):629-37.

- 523 [25] Baetens D, Malaisse-Lagae F, Perrelet A, Orci L. Endocrine pancreas: three-
524 dimensional reconstruction shows two types of islets of langerhans. *Science*.
525 1979;206:1323-5.
- 526 [26] Trimble ER, Halban PA, Wollheim CB, Renold AE. Functional differences between rat
527 islets of ventral and dorsal pancreatic origin. *J Clin Invest*. 1982;69:405-13.
- 528 [27] Trimble ER, Renold AE. Ventral and dorsal areas of rat pancreas: islet hormone content
529 and secretion. *Am J Physiol*. 1981;240:E422-7.
- 530 [28] Leclercq-Meyer V, Marchand J, Malaisse WJ. Insulin and glucagon release from the
531 ventral and dorsal parts of the perfused pancreas of the rat. Effects of glucose, arginine,
532 glucagon and carbamylcholine. *Horm Res*. 1985;21:19-32.
- 533 [29] Tasaka Y, Matsumoto H, Inoue Y, Hirata Y. Contents and secretion of glucagon and
534 insulin in rat pancreatic islets from the viewpoint of their localization in pancreas. *Tohoku J*
535 *Exp Med*. 1989;159:123-30.
- 536 [30] Yukawa M, Takeuchi T, Watanabe T, Kitamura S. Proportions of various endocrine cells
537 in the pancreatic islets of wood mice (*Apodemus speciosus*). *Anat Histol Embryol*.
538 1999;28:13-6.
- 539 [31] Aguayo-Mazzucato C, Sanchez-Soto C, Godinez-Puig V, Gutierrez-Ospina G, Hiriart M.
540 Restructuring of pancreatic islets and insulin secretion in a postnatal critical window. *PLoS*
541 *One*. 2006;1:e35.
- 542 [32] Hornblad A, Cheddad A, Ahlgren U. An improved protocol for optical projection
543 tomography imaging reveals lobular heterogeneities in pancreatic islet and beta-cell mass
544 distribution. *Islets*. 2011;3:204-8.
- 545 [33] Poudel A, Savari O, Striegel DA, Periwal V, Taxy J, Millis JM, et al. Beta-cell destruction
546 and preservation in childhood and adult onset type 1 diabetes. *Endocrine*. 2015;49:693-702.
- 547 [34] Dorrell C, Schug J, Canaday PS, Russ HA, Tarlow BD, Grompe MT, et al. Human islets
548 contain four distinct subtypes of beta cells. *Nat Commun*. 2016;7:11756.
- 549 [35] Ionescu-Tirgoviste C, Gagniuc PA, Gubceac E, Mardare L, Popescu I, Dima S, et al. A
550 3D map of the islet routes throughout the healthy human pancreas. *Sci Rep*. 2015;5:14634.

- 551 [36] Kineman RD, Faught WJ, Frawley LS. Bovine Pituitary-Cells Exhibit a Unique Form of
552 Somatotrope Secretory Heterogeneity. *Endocrinology*. 1990;127:2229-35.
- 553 [37] Ellerkmann E, Nagy GM, Frawley LS. Rapid Augmentation of Prolactin Cell Number and
554 Secretory Capacity by an Estrogen-Induced Factor Released from the Neurointermediate
555 Lobe. *Endocrinology*. 1991;129:838-42.
- 556 [38] Smith PF, Frawley LS, Neill JD. Detection of Lh-Release from Individual Pituitary-Cells
557 by the Reverse Hemolytic Plaque-Assay - Estrogen Increases the Fraction of Gonadotropes
558 Responding to GnRh. *Endocrinology*. 1984;115:2484-6.
- 559 [39] Johnston NR, Mitchell RK, Haythorne E, Pessoa MP, Semplici F, Ferrer J, et al. Beta
560 Cell Hubs Dictate Pancreatic Islet Responses to Glucose. *Cell Metabolism*. 2016;24:389-
561 401.
- 562 [40] Salem VDS, L; Suba, K; Georgiadou, E; Mousavy Gharavy, SN; Akhtar, N; Martin-
563 Alonso, A; Gaboriau, DCA; Rothery, SM; Stylianides, T; Carrat, G; Pullen, TJ; Singh, SP;
564 Hodson, DJ; Leclerc, I; Shapiro, AMJ; Marchetti, P; Briant, LJB; Distaso, W; Ninov, N;
565 Rutter, GA. Leader cells coordinate Ca^{2+} dynamics across pancreatic islets in vivo. . *Nature*
566 *Metabolism*. 2019;In Press.
- 567 [41] Da Silva Xavier G. The Cells of the Islets of Langerhans. *J Clin Med*. 2018;7.
- 568 [42] Orci L, Unger RH. Functional subdivision of islets of Langerhans and possible role of D
569 cells. *Lancet*. 1975;2:1243-4.
- 570 [43] Bosco D, Armanet M, Morel P, Niclauss N, Sgroi A, Muller YD, et al. Unique
571 arrangement of alpha- and beta-cells in human islets of Langerhans. *Diabetes*.
572 2010;59:1202-10.
- 573 [44] Dolensek J, Rupnik MS, Stozar A. Structural similarities and differences between the
574 human and the mouse pancreas. *Islets*. 2015;7:e1024405.
- 575 [45] McEvoy RC. Changes in the volumes of the A-, B-, and D-cell populations in the
576 pancreatic islets during the postnatal development of the rat. *Diabetes*. 1981;30:813-7.

- 577 [46] Rodriguez-Diaz R, Abdulreda MH, Formoso AL, Gans I, Ricordi C, Berggren PO, et al.
578 Innervation patterns of autonomic axons in the human endocrine pancreas. *Cell Metab.*
579 2011;14:45-54.
- 580 [47] Rutter GA, Pullen TJ, Hodson DJ, Martinez-Sanchez A. Pancreatic beta-cell identity,
581 glucose sensing and the control of insulin secretion. *Biochem J.* 2015;466:203-18.
- 582 [48] Iynedjian PB. Mammalian Glucokinase and Its Gene. *Biochemical Journal.* 1993;293:1-
583 13.
- 584 [49] Niemeyer H, de la Luz Cardenas M, Rabajille E, Ureta T, Clark-Turri L, Penaranda J.
585 Sigmoidal kinetics of glucokinase. *Enzyme.* 1975;20:321-33.
- 586 [50] Matschinsky FM, Ellerman JE. Metabolism of glucose in the islets of Langerhans. *J Biol*
587 *Chem.* 1968;243:2730-6.
- 588 [51] Ashcroft SJ, Randle PJ. Control of insulin release by glucose. *Proc R Soc Med.*
589 1968;61:814-5.
- 590 [52] Niemeyer H, Delaluzcardenas M, Rabajille E, Ureta T, Clarkturri L, Penaranda J.
591 Sigmoidal Kinetics of Glucokinase. *Enzyme.* 1975;20:321-33.
- 592 [53] Sekine N, Cirulli V, Regazzi R, Brown LJ, Gine E, Tamaritrodriguez J, et al. Low
593 Lactate-Dehydrogenase and High Mitochondrial Glycerol Phosphate Dehydrogenase in
594 Pancreatic Beta-Cells - Potential Role in Nutrient Sensing. *Journal of Biological Chemistry.*
595 1994;269:4895-902.
- 596 [54] Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Close Linkage of
597 Glucokinase Locus on Chromosome-7p to Early-Onset Non-Insulin-Dependent Diabetes-
598 Mellitus. *Nature.* 1992;356:162-4.
- 599 [55] German MS. Glucose sensing in pancreatic islet beta cells: the key role of glucokinase
600 and the glycolytic intermediates. *Proc Natl Acad Sci U S A.* 1993;90:1781-5.
- 601 [56] Hutton JC, Sener A, Herchuelz A, Atwater I, Kawazu S, Boschero AC, et al. Similarities
602 in the stimulus-secretion coupling mechanisms of glucose- and 2-keto acid-induced insulin
603 release. *Endocrinology.* 1980;106:203-19.

- 604 [57] Matschinsky FM, Meglasson M, Ghosh A, Appel M, Bedoya F, Prentki M, et al.
 605 Biochemical design features of the pancreatic islet cell glucose-sensory system. *Adv Exp*
 606 *Med Biol.* 1986;211:459-69.
- 607 [58] Leclercq-Meyer V, Garcia-Martinez JA, Villanueva-Penacarrillo ML, Valverde I, Malaisse
 608 WJ. In vitro and in vivo insulinotropic action of methyl pyruvate. *Horm Metab Res.*
 609 1995;27:477-81.
- 610 [59] Henquin JC, Dufrane D, Nenquin M. Nutrient control of insulin secretion in isolated
 611 normal human islets. *Diabetes.* 2006;55:3470-7.
- 612 [60] MacDonald MJ. Glucose enters mitochondrial metabolism via both carboxylation and
 613 decarboxylation of pyruvate in pancreatic islets. *Metabolism.* 1993;42:1229-31.
- 614 [61] Khan A, Ling ZC, Landau BR. Quantifying the carboxylation of pyruvate in pancreatic
 615 islets. *J Biol Chem.* 1996;271:2539-42.
- 616 [62] Hellman B, Taljedal IB. Quantitative studies on isolated pancreatic islets of mammals.
 617 Activity and heterogeneity of lactate dehydrogenase in obese-hypoglycemic mice.
 618 *Endocrinology.* 1967;81:125-31.
- 619 [63] Liang Y, Bai G, Doliba N, Buettger C, Wang L, Berner DK, et al. Glucose metabolism
 620 and insulin release in mouse beta HC9 cells, as model for wild-type pancreatic beta-cells.
 621 *Am J Physiol.* 1996;270:E846-57.
- 622 [64] Halestrap AP, Meredith D. The SLC16 gene family-from monocarboxylate transporters
 623 (MCTs) to aromatic amino acid transporters and beyond. *Pflugers Arch.* 2004;447:619-28.
- 624 [65] Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b contribute to
 625 pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1). *Mol Cell Biol.*
 626 2011;31:3182-94.
- 627 [66] Pullen TJ, Sylow L, Sun G, Halestrap AP, Richter EA, Rutter GA. Overexpression of
 628 monocarboxylate transporter-1 (SLC16A1) in mouse pancreatic beta-cells leads to relative
 629 hyperinsulinism during exercise. *Diabetes.* 2012;61:1719-25.

- 630 [67] Pullen TJ, Huising MO, Rutter GA. Analysis of Purified Pancreatic Islet Beta and Alpha
631 Cell Transcriptomes Reveals 11 β -Hydroxysteroid Dehydrogenase (Hsd11b1) as a Novel
632 Disallowed Gene. *Front Genet.* 2017;8:41.
- 633 [68] Gheni G, Ogura M, Iwasaki M, Yokoi N, Minami K, Nakayama Y, et al. Glutamate acts
634 as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin
635 secretion. *Cell Rep.* 2014;9:661-73.
- 636 [69] Casimir M, Rubi B, Frigerio F, Chaffard G, Maechler P. Silencing of the mitochondrial
637 NADH shuttle component aspartate-glutamate carrier AGC1/Aralar1 in INS-1E cells and rat
638 islets. *Biochem J.* 2009;424:459-66.
- 639 [70] Pralong WF, Bartley C, Wollheim CB. Single Islet Beta-Cell Stimulation by Nutrients -
640 Relationship between Pyridine-Nucleotides, Cytosolic Ca²⁺ and Secretion. *Embo J.*
641 1990;9:53-60.
- 642 [71] Denton RM, McCormack JG. On the role of the calcium transport cycle in heart and
643 other mammalian mitochondria. *FEBS Lett.* 1980;119:1-8.
- 644 [72] Kennedy ED, Rizzuto R, Theler JM, Pralong WF, Bastianutto C, Pozzan T, et al.
645 Glucose-stimulated insulin secretion correlates with changes in mitochondrial and cytosolic
646 Ca²⁺ in aequorin-expressing INS-1 cells. *J Clin Invest.* 1996;98:2524-38.
- 647 [73] Rutter GA, Theler JM, Murgia M, Wollheim CB, Pozzan T, Rizzuto R. Stimulated Ca²⁺
648 influx raises mitochondrial free Ca²⁺ to supramicromolar levels in a pancreatic beta-cell line.
649 Possible role in glucose and agonist-induced insulin secretion. *J Biol Chem.*
650 1993;268:22385-90.
- 651 [74] Panten U, Ishida H. Fluorescence of Oxidized Flavoproteins from Perifused Isolated
652 Pancreatic-Islets. *Diabetologia.* 1975;11:569-73.
- 653 [75] Ashcroft SJ, Weerasinghe LC, Bassett JM, Randle PJ. The pentose cycle and insulin
654 release in mouse pancreatic islets. *Biochem J.* 1972;126:525-32.
- 655 [76] Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium
656 channels in isolated rat pancreatic beta-cells. *Nature.* 1984;312:446-8.

- 657 [77] Cook DL, Hales CN. Intracellular ATP directly blocks K⁺ channels in pancreatic B-cells.
658 Nature. 1984;311:271-3.
- 659 [78] Yang SN, Berggren PO. The role of voltage-gated calcium channels in pancreatic beta-
660 cell physiology and pathophysiology. Endocr Rev. 2006;27:621-76.
- 661 [79] Rorsman P, Braun M. Regulation of insulin secretion in human pancreatic islets. Annu
662 Rev Physiol. 2013;75:155-79.
- 663 [80] Sudhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins.
664 Science. 2009;323:474-7.
- 665 [81] Jahn R, Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles.
666 Nature. 2012;490:201-7.
- 667 [82] Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by
668 glucose. Diabetes. 2000;49:1751-60.
- 669 [83] Ferdaoussi M, Dai X, Jensen MV, Wang R, Peterson BS, Huang C, et al. Isocitrate-to-
670 SENP1 signaling amplifies insulin secretion and rescues dysfunctional beta cells. J Clin
671 Invest. 2015;125:3847-60.
- 672 [84] Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R. Reactive
673 oxygen and nitrogen species generation, antioxidant defenses, and beta-cell function: a
674 critical role for amino acids. J Endocrinol. 2012;214:11-20.
- 675 [85] Laybutt DR, Sharma A, Sgroi DC, Gaudet J, Bonner-Weir S, Weir GC. Genetic
676 regulation of metabolic pathways in beta-cells disrupted by hyperglycemia. J Biol Chem.
677 2002;277:10912-21.
- 678 [86] Ashcroft SJ, Bassett JM, Weerasin.Lc, Randle PJ. Pentose Cycle and Insulin Release in
679 Mouse Pancreatic-Islets. Biochemical Journal. 1972;126:525-&.
- 680 [87] Verspohl EJ, Handel M, Ammon HPT. Pentosephosphate Shunt Activity of Rat
681 Pancreatic-Islets - Its Dependence on Glucose-Concentration. Endocrinology.
682 1979;105:1269-74.

- 683 [88] Karaca M, Castel J, Tourrel-Cuzin C, Brun M, Geant A, Dubois M, et al. Exploring
684 functional beta-cell heterogeneity in vivo using PSA-NCAM as a specific marker. *PLoS One*.
685 2009;4:e5555.
- 686 [89] Ullsten S, Lau J, Carlsson PO. Vascular heterogeneity between native rat pancreatic
687 islets is responsible for differences in survival and revascularisation post transplantation.
688 *Diabetologia*. 2015;58:132-9.
- 689 [90] Olsson R, Carlsson PO. A low-oxygenated subpopulation of pancreatic islets constitutes
690 a functional reserve of endocrine cells. *Diabetes*. 2011;60:2068-75.
- 691 [91] Abdulreda MH, Caicedo A, Berggren PO. Transplantation into the anterior chamber of
692 the eye for longitudinal, non-invasive in vivo imaging with single-cell resolution in real-time. *J*
693 *Vis Exp*. 2013:e50466.
- 694 [92] Ali Y, Diez J, Selander L, Zheng X, Edlund H, Berggren PO. The anterior chamber of
695 the eye is a transplantation site that supports and enables visualisation of beta cell
696 development in mice. *Diabetologia*. 2016;59:1007-11.
- 697 [93] Fan Y, Zheng X, Ali Y, Berggren PO, Loo SCJ. Local release of rapamycin by
698 microparticles delays islet rejection within the anterior chamber of the eye. *Sci Rep*.
699 2019;9:3918.
- 700 [94] Ilegems E, Dicker A, Speier S, Sharma A, Bahow A, Edlund PK, et al. Reporter islets in
701 the eye reveal the plasticity of the endocrine pancreas. *Proc Natl Acad Sci U S A*.
702 2013;110:20581-6.
- 703 [95] Tritschler S, Theis FJ, Lickert H, Bottcher A. Systematic single-cell analysis provides
704 new insights into heterogeneity and plasticity of the pancreas. *Molecular Metabolism*.
705 2017;6:974-90.
- 706 [96] Mawla AM, Huising MO. Navigating the Depths and Avoiding the Shallows of Pancreatic
707 Islet Cell Transcriptomes. *Diabetes*. 2019;68:1380-93.
- 708 [97] Baron M, Veres A, Wolock SL, Faust AL, Gaujoux R, Vetere A, et al. A Single-Cell
709 Transcriptomic Map of the Human and Mouse Pancreas Reveals Inter- and Intra-cell
710 Population Structure. *Cell Syst*. 2016;3:346-60 e4.

- 711 [98] Muraro MJ, Dharmadhikari G, Grun D, Groen N, Dielen T, Jansen E, et al. A Single-Cell
712 Transcriptome Atlas of the Human Pancreas. *Cell Syst.* 2016;3:385-94 e3.
- 713 [99] Segerstolpe A, Palasantza A, Eliasson P, Andersson EM, Andreasson AC, Sun X, et al.
714 Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2
715 Diabetes. *Cell Metab.* 2016;24:593-607.
- 716 [100] Wang YJ, Schug J, Won KJ, Liu C, Naji A, Avrahami D, et al. Single-Cell
717 Transcriptomics of the Human Endocrine Pancreas. *Diabetes.* 2016;65:3028-38.
- 718 [101] Wang YJ, Golson ML, Schug J, Traum D, Liu C, Vivek K, et al. Single-Cell Mass
719 Cytometry Analysis of the Human Endocrine Pancreas. *Cell Metab.* 2016;24:616-26.
- 720 [102] Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as
721 a mechanism of diabetic beta cell failure. *Cell.* 2012;150:1223-34.
- 722 [103] Hodson DJ, Mitchell RK, Marselli L, Pullen TJ, Gimeno Brias S, Semplici F, et al.
723 ADCY5 couples glucose to insulin secretion in human islets. *Diabetes.* 2014;63:3009-21.
- 724 [104] Mitchell RK, Mondragon A, Chen L, McGinty JA, French PM, Ferrer J, et al. Selective
725 disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell
726 mass. *Hum Mol Genet.* 2015;24:1390-9.
- 727 [105] Weir GC, Aguayo-Mazzucato C, Bonner-Weir S. beta-cell dedifferentiation in diabetes
728 is important, but what is it? *Islets.* 2013;5:233-7.
- 729 [106] Bader E, Migliorini A, Gegg M, Moruzzi N, Gerdes J, Roscioni SS, et al. Identification
730 of proliferative and mature beta-cells in the islets of Langerhans. *Nature.* 2016;535:430-4.
- 731 [107] Klochendler A, Caspi I, Corem N, Moran M, Friedlich O, Elgavish S, et al. The Genetic
732 Program of Pancreatic beta-Cell Replication In Vivo. *Diabetes.* 2016;65:2081-93.
- 733 [108] Teo AKK, Lim CS, Cheow LF, Kin T, Shapiro JA, Kang NY, et al. Single-cell analyses
734 of human islet cells reveal de-differentiation signatures. *Cell Death Discov.* 2018;4:14.
- 735 [109] Lawlor N, George J, Bolisetty M, Kursawe R, Sun L, Sivakamasundari V, et al. Single-
736 cell transcriptomes identify human islet cell signatures and reveal cell-type-specific
737 expression changes in type 2 diabetes. *Genome Res.* 2017;27:208-22.

738 [110] van der Meulen T, Mawla AM, DiGruccio MR, Adams MW, Nies V, Dolleman S, et al.
 739 Virgin Beta Cells Persist throughout Life at a Neogenic Niche within Pancreatic Islets. *Cell*
 740 *Metab.* 2017;25:911-26 e6.

741 [111] Arrojo EDR, Lev-Ram V, Tyagi S, Ramachandra R, Deerinck T, Bushong E, et al. Age
 742 Mosaicism across Multiple Scales in Adult Tissues. *Cell Metab.* 2019.

743 [112] Singh SP, Janjuha S, Hartmann T, Kayisoglu O, Konantz J, Birke S, et al. Different
 744 developmental histories of beta-cells generate functional and proliferative heterogeneity
 745 during islet growth. *Nat Commun.* 2017;8:664.

746 [113] Thompson PJ, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A. Targeted
 747 Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. *Cell Metab.* 2019;29:1045-
 748 60 e10.

749 [114] Byrnes LE, Wong DM, Subramaniam M, Meyer NP, Gilchrist CL, Knox SM, et al.
 750 Lineage dynamics of murine pancreatic development at single-cell resolution. *Nat Commun.*
 751 2018;9:3922.

752 [115] Gittes GK. Developmental biology of the pancreas: a comprehensive review. *Dev Biol.*
 753 2009;326:4-35.

754 [116] Furuyama K, Chera S, van Gurp L, Oropeza D, Ghila L, Damond N, et al. Diabetes
 755 relief in mice by glucose-sensing insulin-secreting human alpha-cells. *Nature.* 2019;567:43-
 756 8.

757 [117] Meda P, Bosco D, Chanson M, Giordano E, Vallar L, Wollheim C, et al. Rapid and
 758 Reversible Secretion Changes during Uncoupling of Rat Insulin-Producing Cells. *Journal of*
 759 *Clinical Investigation.* 1990;86:759-68.

760 [118] Speier S, Gjinovci A, Charollais A, Meda P, Rupnik M. Cx36-mediated coupling
 761 reduces beta-cell heterogeneity, confines the stimulating glucose concentration range, and
 762 affects insulin release kinetics. *Diabetes.* 2007;56:1078-86.

763 [119] Benninger RK, Hutchens T, Head WS, McCaughey MJ, Zhang M, Le Marchand SJ, et
 764 al. Intrinsic islet heterogeneity and gap junction coupling determine spatiotemporal Ca^{2+} (+)
 765 wave dynamics. *Biophys J.* 2014;107:2723-33.

- 766 [120] Benninger RK, Zhang M, Head WS, Satin LS, Piston DW. Gap junction coupling and
767 calcium waves in the pancreatic islet. *Biophys J.* 2008;95:5048-61.
- 768 [121] Meda P, Deneff JF, Perrelet A, Orci L. Nonrandom distribution of gap junctions
769 between pancreatic beta-cells. *Am J Physiol.* 1980;238:C114-9.
- 770 [122] Serre-Beinier V, Bosco D, Zulianello L, Charollais A, Caille D, Charpantier E, et al.
771 Cx36 makes channels coupling human pancreatic beta-cells, and correlates with insulin
772 expression. *Hum Mol Genet.* 2009;18:428-39.
- 773 [123] Meda P. Gap junction proteins are key drivers of endocrine function. *Biochim Biophys*
774 *Acta Biomembr.* 2018;1860:124-40.
- 775 [124] Hodson DJ, Mitchell RK, Bellomo EA, Sun G, Vinet L, Meda P, et al. Lipotoxicity
776 disrupts incretin-regulated human beta cell connectivity. *J Clin Invest.* 2013;123:4182-94.
- 777 [125] Emfinger CH, Lorincz R, Wang Y, York NW, Singareddy SS, Ikle JM, et al. Beta-cell
778 excitability and excitability-driven diabetes in adult Zebrafish islets. *Physiol Rep.*
779 2019;7:e14101.
- 780 [126] Janjuha S, Singh SP, Tsakmaki A, Mousavy Gharavy SN, Murawala P, Konantz J, et
781 al. Age-related islet inflammation marks the proliferative decline of pancreatic beta-cells in
782 zebrafish. *Elife.* 2018;7.
- 783 [127] Miller AC, Whitebitch AC, Shah AN, Marsden KC, Granato M, O'Brien J, et al. A
784 genetic basis for molecular asymmetry at vertebrate electrical synapses. *Elife.* 2017;6.
- 785 [128] Granger CWJ. Investigating Causal Relations by Econometric Models and Cross-
786 Spectral Methods. *Econometrica.* 1969;37:424-38.
- 787 [129] Bennett BD, Jetton TL, Ying G, Magnuson MA, Piston DW. Quantitative subcellular
788 imaging of glucose metabolism within intact pancreatic islets. *J Biol Chem.* 1996;271:3647-
789 51.
- 790 [130] Oram RA, Sims EK, Evans-Molina C. Beta cells in type 1 diabetes: mass and function;
791 sleeping or dead? *Diabetologia.* 2019;62:567-77.
- 792 [131] Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two
793 independent cell lineages. *Development.* 2000;127:2317-22.

794 [132] Dahan T, Ziv O, Horwitz E, Zemmour H, Lavi J, Swisa A, et al. Pancreatic beta-Cells
 795 Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes. *Diabetes*.
 796 2017;66:426-36.

797 [133] Ediger BN, Lim HW, Juliana C, Groff DN, Williams LT, Dominguez G, et al. LIM
 798 domain-binding 1 maintains the terminally differentiated state of pancreatic beta cells. *J Clin*
 799 *Invest*. 2017;127:215-29.

800 [134] Gutierrez GD, Bender AS, Cirulli V, Mastracci TL, Kelly SM, Tsigos A, et al.
 801 Pancreatic beta cell identity requires continual repression of non-beta cell programs. *J Clin*
 802 *Invest*. 2017;127:244-59.

803 [135] Katsuta H, Akashi T, Katsuta R, Nagaya M, Kim D, Arinobu Y, et al. Single pancreatic
 804 beta cells co-express multiple islet hormone genes in mice. *Diabetologia*. 2010;53:128-38.

805 [136] Chiang MK, Melton DA. Single-cell transcript analysis of pancreas development. *Dev*
 806 *Cell*. 2003;4:383-93.

807 [137] Riedel MJ, Asadi A, Wang R, Ao Z, Warnock GL, Kieffer TJ. Immunohistochemical
 808 characterisation of cells co-producing insulin and glucagon in the developing human
 809 pancreas. *Diabetologia*. 2012;55:372-81.

810 [138] De Krijger RR, Aanstoot HJ, Kranenburg G, Reinhard M, Visser WJ, Bruining GJ. The
 811 midgestational human fetal pancreas contains cells coexpressing islet hormones. *Dev Biol*.
 812 1992;153:368-75.

813 [139] Polak M, Bouchareb-Banaei L, Scharfmann R, Czernichow P. Early pattern of
 814 differentiation in the human pancreas. *Diabetes*. 2000;49:225-32.

815 [140] Liu JS, Hebrok M. All mixed up: defining roles for beta-cell subtypes in mature islets.
 816 *Genes Dev*. 2017;31:228-40.

817 [141] Nasteska D, Hodson DJ. The role of beta cell heterogeneity in islet function and insulin
 818 release. *J Mol Endocrinol*. 2018;61:R43-R60.

819 [142] Zhang J, McKenna LB, Bogue CW, Kaestner KH. The diabetes gene Hhex maintains
 820 delta-cell differentiation and islet function. *Genes Dev*. 2014;28:829-34.

821

Figure 1

Figure 2